Cowen & Co. Sticks to Their Buy Rating for Erytech Pharma SA


Cowen & Co. analyst Boris Peaker maintained a Buy rating on Erytech Pharma SA (NASDAQ: ERYP) today. The company’s shares opened today at $20.48.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.6% and a 52.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Erytech Pharma SA has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.33 and a one-year low of $17.50. Currently, Erytech Pharma SA has an average volume of 477.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts